Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609094 | 0.91 | GPR119 (0.51) | GPR119CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL1575179 | 0.89 | GPR119 (0.66) | GPR119MEN1KMT2ASCN9A | |
| SCHEMBL2568684 | 0.87 | GPR119 (0.54) | GPR119CRBN | |
| SCHEMBL14621454 | 0.83 | GPR119 (0.49) | GPR119CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL1575158 | 0.81 | GPR119 (0.66) | GPR119SCN9A | |
| SCHEMBL1575954 | 0.81 | GPR119 (0.66) | GPR119SCN9A | |
| SCHEMBL3613265 | 0.81 | GPR119 (0.59) | GPR119 | |
| SCHEMBL1576249 | 0.81 | GPR119 (0.66) | GPR119 | |
| SCHEMBL1575680 | 0.81 | GPR119 (0.65) | GPR119SCN9A | |
| SCHEMBL1575629 | 0.79 | GPR119 (0.68) | GPR119SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20100063081-A1 | CPCR Agonists | PROSIDION LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172358-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885CHRM2 564/4885CHRM5 664/4885 |
| US-20100063081-A1 | CPCR Agonists | GPR119, GCGR, GLP1R | GPR119 1/4885CHRM2 276/4885CHRM5 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.